DOCSLIB.ORG

Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors Neurochemical Research (2019) 44:735–750 https://doi.org/10.1007/s11064-018-02712-1 REVIEW PAPER Therapeutic Effect of Agmatine on Neurological Disease: Focus on Ion Channels and Receptors Sumit Barua1 · Jong Youl Kim1 · Jae Young Kim1 · Jae Hwan Kim4 · Jong Eun Lee1,2,3 Received: 15 October 2018 / Revised: 19 December 2018 / Accepted: 24 December 2018 / Published online: 4 January 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract The central nervous system (CNS) is the most injury-prone part of the mammalian body. Any acute or chronic, central or peripheral neurological disorder is related to abnormal biochemical and electrical signals in the brain cells. As a result, ion channels and receptors that are abundant in the nervous system and control the electrical and biochemical environment of the CNS play a vital role in neurological disease. The N-methyl-D-aspartate receptor, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl) propanoic acid receptor, kainate receptor, acetylcholine receptor, serotonin receptor, α2-adrenoreceptor, and acid-sensing ion channels are among the major channels and receptors known to be key components of pathophysiological events in the CNS. The primary amine agmatine, a neuromodulator synthesized in the brain by decarboxylation of L-arginine, can regu- late ion channel cascades and receptors that are related to the major CNS disorders. In our previous studies, we established that agmatine was related to the regulation of cell differentiation, nitric oxide synthesis, and murine brain endothelial cell migration, relief of chronic pain, cerebral edema, and apoptotic cell death in experimental CNS disorders. In this review, we will focus on the pathophysiological aspects of the neurological disorders regulated by these ion channels and receptors, and their interaction with agmatine in CNS injury. Keywords Agmatine · Ion channels · Receptors · Neurodegenerative disease · Receptor blockade Abbreviations Sumit Barua and Jong Youl Kim have contributed equally to this work. CNS Central nervous system PNS Peripheral nervous system * Jong Eun Lee AD Alzheimer’s disease [email protected] PD Parkinson’s disease Sumit Barua HD Huntington’s disease [email protected] ADC Arginine decarboxylase Jong Youl Kim ROS Reactive oxygen species [email protected] NF-κB Nuclear factor kappa B Jae Young Kim TBI Traumatic brain injury [email protected] NO Nitric oxide Jae Hwan Kim SCI Spinal cord injury [email protected] BMP Bone morphogenetic protein 1 Department of Anatomy, Yonsei University College Aβ Amyloid-beta of Medicine, 50-1 Yonsei-Ro, Seodaemun-gu, Seoul 03722, Nrf2 Nuclear factor (erythroid derived 2)-like 2 Republic of Korea MPTP 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyri- 2 Brain Korea 21 PLUS Project for Medical Science, Yonsei dine University College of Medicine, 50 Yonsei-Ro, Seoul 03722, MES Maximal electroshock seizures Republic of Korea PTZ Pentylenetetrazole 3 Brain Research Institute, Yonsei University College NMDAR N-Methyl-D-aspartate receptor of Medicine, 50 Yonsei-Ro, Seoul 03722, Republic of Korea AMPAR α-Amino-3-hydroxy-5-methylisoxazole-4- 4 Center for Neuroscience Imaging Research (CNIR), Insititute propionic acid receptor for Basic Science, Sungkyunkwan University, Seoul, NOS Nitric oxide synthase Republic of Korea Vol.:(0123456789)1 3 736 Neurochemical Research (2019) 44:735–750 KAR Kainite receptor channel-related diseases termed channelopathies, which GPCR G protein-coupled receptor overlap with acute and chronic neurodegenerative disorders CDS Clonidine displacing substance such as ischemic stroke, traumatic injury, epilepsy, Alzhei- AChR Acetylcholine mer’s disease (AD), schizophrenia, and Huntington’s disease mAChR Muscarinic acetylcholine receptor (HD) [1]. The majority of neurodegenerative diseases are nAChR Nicotinic acetylcholine receptor related to cell death caused by disrupted ion channels and 5-HT 5-Hydroxytryptamine receptors or metabolic functions of neuronal cells [2–5]. In VDCC Voltage-dependent calcium channel the healthy brain, ionic homeostasis is a major component LVA Low-voltage activated of neuronal information transmission via action potentials, HVA High-voltage activated which are also related to synaptic transmission between pre- ENaC/DEG Epithelial Na+ channel/degenerin synaptic and postsynaptic neurons. Loss of synaptic function ASIC Acid-sensing ion channel due to low energy supply in neurodegenerative disorders EL/IL Extracellular/intracellular loops leads to attenuation of ion homeostasis [6, 7]. In the diseased brain, ion homeostasis is maintained by a series of ion chan- nels in brain cells, predominantly in neuron, astrocyte and Introduction microglia, and a myriad of ions that are transported across the cell membrane via those channels (Table 1). Among the Ion channels and receptors are the macromolecular mem- range of associated ions, potassium, sodium, chloride, and brane pores that traffic a series of ions(Na +, K+, Ca2+, Cl−) calcium collectively play a pivotal role in cellular damage and chemicals (neurotransmitters, hormones etc.) in or out [1, 8]. Following central nervous system (CNS) injury, the of the cells and propagate the biochemical and electrical well-orchestrated ion exchange across the membrane via ion signals. Functional initiation of ion channels requires stimuli channels or receptors is disrupted and brain cells lose their such as ligand binding, chemical/mechanical changes, and normal function, leading to death. altered membrane potentials. Therefore, any iatrogenic, Agmatine, an arginine-derived primary amino acid autoimmune, toxic, or genetic dysfunction can cause ion found in the nerve cell body and synaptic terminals, acts as Table 1 Major ion channels and receptors to which agmatine act as a ligand and modulates their functions Ion channel/receptor Ligand Conducting ions Related neurological disorders References + 2+ + NMDA L-Glutamate, NMDA, glycine Na , Ca , K Stoke and traumatic injury, [38, 131, 133, 134] AD, HD, pain, schizophrenia, depression + + 2+ AMPA and kinate L-Glutamate, AMPA Na , K , less Ca Stoke and traumatic injury, [98] AD, epilepsy schizophrenia, depression, amyotrophic lateral sclerosis, autism α2-Adenoceptor: α2-Adenoceptor: epinephrine α2-Adenoceptor : K+, Na+ and Pain, panic disorder, addiction, [164–172] imidazoline recep- norepinephrine, α-methyl H+ depression, anxiety, hyperten- tors DOPA and others Imidazoline receptor: Ca+ sion Imidazoline receptors: imidazo- line compounds AChR Acetylcholine nicotine Na+, Ca2+, K+ Myasthenia gravis, epilepsy, [57, 60, 62–64] AD, PD, schizophrenia, Tou- rette’s syndrome, idiopathic inflammatory bowel disease, addiction, anxiety, depression VDCC Membrane potential Ca2+ Epilepsy, seizures, AD, pain, [77, 78, 80] autism spectrum disorder, migraine, anxiety, depression ASICs Extracellular protons Na+, less Ca2+ Ischemic stroke, traumatic [88, 92, 99, 120] injury, pain, HD, PD, multiple sclerosis, glioblastoma, epilepsy Serotonin (5-HT) Different serotonergic com- Na+, Ca2+, K+ by 5-HT3 AD, anxiety, depression, [107, 108, 130, 169] pounds seizure locomotor activity, aggression 1 3 Neurochemical Research (2019) 44:735–750 737 a neuromodulator that mimics the functional properties of cation [30]. Agmatine is also suggested to behave as mono- other neurotransmitters [9, 10]. The enzyme arginine decar- valent when it interacts with the microscopic channels and boxylase (ADC) synthesizes agmatine by decarboxylation of divalent as a macroscopic charge transfer [30]. L-arginine [11]. On the other hand, studies suggested that in Agmatine can be metabolized into putres- the mammal lacking ADC, decarboxylation of L-arginine is cine by the enzyme agmatinase or oxidized into catalyzed by the ornithine decarboxylase enzyme. Agmatine- γ-guanidinobutyraldehyde by diamine oxidase (Fig. 1). expressing cells have been found in all regions of the brain Agmatinase belongs to the family of hydrolases, those acting such as the hypothalamus, frontal cortex, striatum, medulla, on carbon–nitrogen bonds other than peptide bonds, specifi- hippocampus, and locus coeruleus along with measurable cally in linear amidines, then synthesizes putrescine, one of ADC activity [9, 10, 12–16]. However, the highest number polyamines. Putrescine is metabolized further into the poly- of these cells was observed in the paraventricular (PVN) and amines, spermidine and spermine [31]. On the other hand, supraoptic (SON) nuclei of the hypothalamus, which also diamine oxidase deaminates oxidatively diamines to produce exhibited the highest ADC activity. Diverse mechanisms of aldehydes, ammonia and hydrogen peroxide. Therefore, the neuroprotection by agmatine in response to neurodegenera- amino group of agmatine is metabolized by the action of tive diseases have been reported by many research groups, diamine oxidase to become γ-guanidinobutylbutylic acid- such as blocking of harmful ion channels, suppressing harm- aldehyde, and is further metabolized to γ-guanidinobutyric ful reactive oxygen species (ROS), promoting neurogenesis, acid by aldehyde dehydrogenase (Fig. 1). Agmatine has two angiogenesis, reducing glial scars etc [17–20]. In a recent reactive groups, which increased its possibility of various review, Laube and Bernstein preciously reviewed the recent chemical reactions in vivo. With this potentiality for bio- studies about the agmatine metabolism and clinical applica- chemical reactions, agmatine has been used as an experi- tion including nervous system [21]. In acute brain diseases, mental
Load more

Recommended publications
  • NISCH Antibody Order 021-34695924 [email protected] Support 400-6123-828 50Ul [email protected] 100 Ul √ √ Web
    TD13185 NISCH Antibody Order 021-34695924 [email protected] Support 400-6123-828 50ul [email protected] 100 uL √ √ Web www.ab-mart.com.cn Description: Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane- associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen- activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension (By similarity). Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons (By similarity). Acts as a modulator of Rac-regulated signal transduction pathways (By similarity). Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity (By similarity). Also blocks Pak- independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation (By similarity). Inhibits also LIMK1 kinase activity by reducing LIMK1 'Tyr-508' phosphorylation (By similarity). Inhibits Rac- induced cell migration and invasion in breast and colon epithelial cells (By similarity). Inhibits lamellipodia formation, when overexpressed (By similarity). Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement
    [Show full text]
  • Allantoin Activates Imidazoline I-3 Receptors to Enhance Insulin
    Tsai et al. Nutrition & Metabolism 2014, 11:41 http://www.nutritionandmetabolism.com/content/11/1/41 RESEARCH Open Access Allantoin activates imidazoline I-3 receptors to enhance insulin secretion in pancreatic β-cells Cheng-Chia Tsai1, Li-Jen Chen2,3, Ho-Shan Niu3, Kun-Ming Chung4, Juei-Tang Cheng5* and Kao-Chang Lin4,6 Abstract Background: Imidazoline I3 receptors (I-3R) can regulate insulin secretion in pancreatic β-cells. It has been indicated that allantoin ameliorates hyperglycemia by activating imidazoline I2 receptors (I-2R). Thus, the effect of allantoin on I-3R is identified in the present study. Methods: We used male Wistar rats to screen allantoin’s ability for lowering of blood glucose and stimulation of insulin secretion. Chinese hamster ovary-K1 cells transfected with imidazoline receptors (NISCH-CHO-K1 cells) were also applied to characterize the direct effect of allantoin on this receptor. Additionally, KU14R as specific antagonist was treated to block I-3R in rats and in the cultured pancreatic β-cells named Min 6 cells. Results: In rats, allantoin decreased blood sugar with an increase in plasma insulin. Also, allantoin enhanced calcium influx into NISCH-CHO-K1 cells in a way similar to agmatine, an I-R agonist. Moreover, KU14R dose-dependently blocked allantoin-induced insulin secretion both in Min 6 cells and in Wistar rats. Conclusion: Allantoin can activate I-3R to enhance insulin secretion for lowering of blood sugar in Wistar rats. Thus, allantoin may provide beneficial effects as a supplement for diabetic patients after clinical trials. Keywords: Allantoin, Insulin secretion, Imidazoline I3 receptor, CHO-K1, NISCH Background is mentioned to reduce blood glucose [11,12].
    [Show full text]
  • Characterization of a Domoic Acid Binding Site from Pacific Razor Clam
    Aquatic Toxicology 69 (2004) 125–132 Characterization of a domoic acid binding site from Pacific razor clam Vera L. Trainer∗, Brian D. Bill NOAA Fisheries, Northwest Fisheries Science Center, Marine Biotoxin Program, 2725 Montlake Blvd. E., Seattle, WA 98112, USA Received 5 November 2003; received in revised form 27 April 2004; accepted 27 April 2004 Abstract The Pacific razor clam, Siliqua patula, is known to retain domoic acid, a water-soluble glutamate receptor agonist produced by diatoms of the genus Pseudo-nitzschia. The mechanism by which razor clams tolerate high levels of the toxin, domoic acid, in their tissues while still retaining normal nerve function is unknown. In our study, a domoic acid binding site was solubilized from razor clam siphon using a combination of Triton X-100 and digitonin. In a Scatchard analysis using [3H]kainic acid, the partially-purified membrane showed two distinct receptor sites, a high affinity, low capacity site with a KD (mean ± S.E.) of 28 ± 9.4 nM and a maximal binding capacity of 12 ± 3.8 pmol/mg protein and a low affinity, high capacity site with a mM affinity for radiolabeled kainic acid, the latter site which was lost upon solubilization. Competition experiments showed that the rank order potency for competitive ligands in displacing [3H]kainate binding from the membrane-bound receptors was quisqualate > ibotenate > iodowillardiine = AMPA = fluorowillardiine > domoate > kainate > l-glutamate. At high micromolar concentrations, NBQX, NMDA and ATPA showed little or no ability to displace [3H]kainate. In contrast, Scatchard analysis 3 using [ H]glutamate showed linearity, indicating the presence of a single binding site with a KD and Bmax of 500 ± 50 nM and 14 ± 0.8 pmol/mg protein, respectively.
    [Show full text]
  • Decarboxylation What Is Decarboxylation?
    Decarboxylation What is decarboxylation? Decarboxylation is the removal of a carboxyl group when a compound is exposed to light or heat. A carboxyl group is a grouping of carbon, oxygen, and hydrogen atoms in the form of COOH. When a compound is decarboxylated, this group is released in the form of carbon dioxide. Decarboxylation of cannabinoids When considering the decarboxylation of cannabinoids, it is important to note that this reaction is what causes the neutral acidic cannabinoids to turn into the active cannabinoids found in most products on the market. Both the neutral and acidic cannabinoids are naturally found in the cannabis plant. The active cannabinoids that have psychoactive properties are what occur after decarboxylation. Below is the mechanism for the conversion of THCA to THC. https://www.leafscience.com/2017/04/13/what-is-thca/ Heating THCA converts it to THC by kicking off the carboxyl group seen on the right side of the THCA molecule. Once the carboxyl group is released from the THCA it forms carbon dioxide and the THC compound. The THC is now ready for use in different products and will provide the psychoactive effects that popularized this compound. This simple reaction is all it takes to convert the acidic cannabinoids to their active counterparts. Cannabinolic acid (CBDA) and CBD are both another example of this process. Decarboxylation process Light can start the decarboxylation process after a period of time, but heat is the more common element used. There are different methods to decarboxylate cannabis depending on user preference. In the industry, dabs, vapes and joints decarboxylate instantly when heat is applied to the product.
    [Show full text]
  • Optimization of the Decarboxylation Reaction in Cannabis
    APPLICATION NOTE FT-IR Spectroscopy Authors: Dr. Markus Roggen1 Antonio M. Marelli1 Doug Townsend2 Ariel Bohman2 1Outco SanDiego, CA 2PerkinElmer, Inc. Shelton, CT. Optimization of the Decarboxylation Reaction Introduction The production of cannabis in Cannabis Extract extracts and oils for medicinal and recreational products has increased significantly in North America. This growth has been driven by both market demand in newly legalized states and patient demand for a greater diversity in cannabis products.1,2,3 Most cannabis extraction processes, independent of solvent or instrument choice, undergo a decarboxylation step whereby the carboxylic acid functional group is removed from the cannabinoids. The decarboxylation reaction converts the naturally occurring acid forms of the cannabinoids, e.g. tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), to their more potent neutral forms, e.g. tetrahydrocannabinol (THC) and cannabidiol (CBD). Because the carboxylic acid group is thermally labile, the industry typically applies a heat source, and at times a catalyst, to decarboxylate the cannabinoids. The heat-promoted decarboxylation reaction has been Decarboxylation Reaction discussed at length within the industry, but an extensive Decarboxylation was achieved by heating the cannabis extract in 4, 5, 6 literature search reveals very few papers on the process. a oil bath with a programmable hot plate. An overhead stirrer The data available represents a large spectrum of reaction was utilized to promote even heat distribution throughout the conditions, including a range in reaction temperature, time experiment. Oil bath and extract temperatures were recorded and instrumental setup. As such, there is a lack of universal every five minutes throughout the 80-minute heating process.
    [Show full text]
  • Protocol for a Randomised Controlled Trial: Efficacy of Donepezil Against
    BMJ Open: first published as 10.1136/bmjopen-2013-003533 on 25 September 2013. Downloaded from Open Access Protocol Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson’s disease (EDAP) Hideyuki Sawada, Tomoko Oeda To cite: Sawada H, Oeda T. ABSTRACT ARTICLE SUMMARY Protocol for a randomised Introduction: Psychosis, including hallucinations and controlled trial: efficacy of delusions, is one of the important non-motor problems donepezil against psychosis Strengths and limitations of this study in patients with Parkinson’s disease (PD) and is in Parkinson’s disease ▪ In previous randomised controlled trials for (EDAP). BMJ Open 2013;3: possibly associated with cholinergic neuronal psychosis the efficacy was investigated in patients e003533. doi:10.1136/ degeneration. The EDAP (Efficacy of Donepezil against who presented with psychosis and the primary bmjopen-2013-003533 Psychosis in PD) study will evaluate the efficacy of endpoint was improvement of psychotic symp- donepezil, a brain acetylcholine esterase inhibitor, for toms. By comparison, this study is designed to prevention of psychosis in PD. ▸ Prepublication history for evaluate the prophylactic effect in patients this paper is available online. Methods and analysis: Psychosis is assessed every without current psychosis. Because psychosis To view these files please 4 weeks using the Parkinson Psychosis Questionnaire may be overlooked and underestimated it is visit the journal online (PPQ) and patients with PD whose PPQ-B score assessed using a questionnaire, Parkinson (http://dx.doi.org/10.1136/ (hallucinations) and PPQ-C score (delusions) have Psychosis Questionnaire (PPQ) every 4 weeks. bmjopen-2013-003533). been zero for 8 weeks before enrolment are ▪ The strength of this study is its prospective randomised to two arms: patients receiving donepezil design using the preset definition of psychosis Received 3 July 2013 hydrochloride or patients receiving placebo.
    [Show full text]
  • Targeting Glycine Reuptake in Alcohol Seeking and Relapse
    JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. TITLE PAGE Targeting Glycine Reuptake in Alcohol Seeking and Relapse Valentina Vengeliene, Martin Roßmanith, Tatiane T. Takahashi, Daniela Alberati, Berthold Behl, Anton Bespalov, Rainer Spanagel Downloaded from The primary laboratory of origin: Institute of Psychopharmacology, Central Institute of jpet.aspetjournals.org Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; at ASPET Journals on September 30, 2021 VV, MR, TTT, RS: Institute of Psychopharmacology, Central Institute of Mental Health, Faculty of Medicine Mannheim, Heidelberg University, Germany; DA: Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, CH-4070 Basel, Switzerland; BB, AB: Department of Neuroscience Research, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany; AB: Department of Psychopharmacology, Pavlov Medical University, St Petersburg, Russia JPET #244822 JPET Fast Forward. Published on January 24, 2018 as DOI: 10.1124/jpet.117.244822 This article has not been copyedited and formatted. The final version may differ from this version. RUNNING TITLE GlyT1 in Alcohol Seeking and Relapse Corresponding author with complete address: Valentina Vengeliene, Institute of Psychopharmacology, Central Institute of Mental Health (CIMH), J5, 68159 Mannheim, Germany Email: [email protected], phone: +49-621-17036261; fax: +49-621- Downloaded from 17036255 jpet.aspetjournals.org The number of text pages: 33 Number of tables: 0 Number of figures: 6 Number of references: 44 at ASPET Journals on September 30, 2021 Number of words in the Abstract: 153 Number of words in the Introduction: 729 Number of words in the Discussion: 999 A recommended section assignment to guide the listing in the table of content: Drug Discovery and Translational Medicine 2 JPET #244822 JPET Fast Forward.
    [Show full text]
  • Nicotine and Neurotransmitters
    Module 2 —Legal Doesn’t Mean Harmless Overview Overview Summary This module focuses on how two drugs, nicotine and alcohol, change the functioning of the brain and body. Both drugs are widely used in the community, and for adults, using them is legal. Nonetheless, both alcohol and nicotine can have a strong impact on the functioning of the brain. Each can cause a number of negative effects on the body and brain, ranging from mild symptoms to addiction. The goal of this module is to help students understand that, although nicotine and alcohol are legal for adults, they are not harmless substances. Students will learn about how nicotine and alcohol change or disrupt the process of neurotransmission. Students will explore information on the short- and long- term effects of these two drugs, and also learn why these drugs are illegal for children and teens. Through the media, students are exposed to a great deal of information about alcohol and tobacco, much of which is misleading or scientifically inaccurate. This module will provide information on what researchers have learned about how nicotine and alcohol change the brain, and the resulting implications for safety and health. Learning Objectives At the end of this module: • Students can explain how nicotine disrupts neurotransmission. • Students can explain how alcohol use may harm the brain and the body. • Students understand how alcohol can intensify the effect of other drugs. • Students can define addiction and understand its basis in the brain. • Students draw conclusions about why our society regulates the use of nicotine and alcohol for young people.
    [Show full text]
  • A Human Stem Cell-Derived Test System for Agents Modifying Neuronal N
    Archives of Toxicology (2021) 95:1703–1722 https://doi.org/10.1007/s00204-021-03024-0 IN VITRO SYSTEMS A human stem cell‑derived test system for agents modifying neuronal 2+ N‑methyl‑D‑aspartate‑type glutamate receptor Ca ‑signalling Stefanie Klima1,2 · Markus Brüll1 · Anna‑Sophie Spreng1,3 · Ilinca Suciu1,3 · Tjalda Falt1 · Jens C. Schwamborn4 · Tanja Waldmann1 · Christiaan Karreman1 · Marcel Leist1,5 Received: 28 October 2020 / Accepted: 4 March 2021 / Published online: 13 March 2021 © The Author(s) 2021 Abstract Methods to assess neuronal receptor functions are needed in toxicology and for drug development. Human-based test systems that allow studies on glutamate signalling are still scarce. To address this issue, we developed and characterized pluripotent stem cell (PSC)-based neural cultures capable of forming a functional network. Starting from a stably proliferating neu- roepithelial stem cell (NESC) population, we generate “mixed cortical cultures” (MCC) within 24 days. Characterization by immunocytochemistry, gene expression profling and functional tests (multi-electrode arrays) showed that MCC contain various functional neurotransmitter receptors, and in particular, the N-methyl-D-aspartate subtype of ionotropic glutamate receptors (NMDA-R). As this important receptor is found neither on conventional neural cell lines nor on most stem cell- derived neurons, we focused here on the characterization of rapid glutamate-triggered Ca2+ signalling. Changes of the intra- 2+ cellular free calcium ion concentration ([Ca ]i) were measured by fuorescent imaging as the main endpoint, and a method to evaluate and quantify signals in hundreds of cells at the same time was developed. We observed responses to glutamate in the low µM range.
    [Show full text]
  • Citric Acid Cycle
    CHEM464 / Medh, J.D. The Citric Acid Cycle Citric Acid Cycle: Central Role in Catabolism • Stage II of catabolism involves the conversion of carbohydrates, fats and aminoacids into acetylCoA • In aerobic organisms, citric acid cycle makes up the final stage of catabolism when acetyl CoA is completely oxidized to CO2. • Also called Krebs cycle or tricarboxylic acid (TCA) cycle. • It is a central integrative pathway that harvests chemical energy from biological fuel in the form of electrons in NADH and FADH2 (oxidation is loss of electrons). • NADH and FADH2 transfer electrons via the electron transport chain to final electron acceptor, O2, to form H2O. Entry of Pyruvate into the TCA cycle • Pyruvate is formed in the cytosol as a product of glycolysis • For entry into the TCA cycle, it has to be converted to Acetyl CoA. • Oxidation of pyruvate to acetyl CoA is catalyzed by the pyruvate dehydrogenase complex in the mitochondria • Mitochondria consist of inner and outer membranes and the matrix • Enzymes of the PDH complex and the TCA cycle (except succinate dehydrogenase) are in the matrix • Pyruvate translocase is an antiporter present in the inner mitochondrial membrane that allows entry of a molecule of pyruvate in exchange for a hydroxide ion. 1 CHEM464 / Medh, J.D. The Citric Acid Cycle The Pyruvate Dehydrogenase (PDH) complex • The PDH complex consists of 3 enzymes. They are: pyruvate dehydrogenase (E1), Dihydrolipoyl transacetylase (E2) and dihydrolipoyl dehydrogenase (E3). • It has 5 cofactors: CoASH, NAD+, lipoamide, TPP and FAD. CoASH and NAD+ participate stoichiometrically in the reaction, the other 3 cofactors have catalytic functions.
    [Show full text]
  • Lecture: 28 TRANSAMINATION, DEAMINATION and DECARBOXYLATION
    Lecture: 28 TRANSAMINATION, DEAMINATION AND DECARBOXYLATION Protein metabolism is a key physiological process in all forms of life. Proteins are converted to amino acids and then catabolised. The complete hydrolysis of a polypeptide requires mixture of peptidases because individual peptidases do not cleave all peptide bonds. Both exopeptidases and endopeptidases are required for complete conversion of protein to amino acids. Amino acid metabolism The amino acids not only function as energy metabolites but also used as precursors of many physiologically important compounds such as heme, bioactive amines, small peptides, nucleotides and nucleotide coenzymes. In normal human beings about 90% of the energy requirement is met by oxidation of carbohydrates and fats. The remaining 10% comes from oxidation of the carbon skeleton of amino acids. Since the 20 common protein amino acids are distinctive in terms of their carbon skeletons, amino acids require unique degradative pathway. The degradation of the carbon skeletons of 20 amino acids converges to just seven metabolic intermediates namely. i. Pyruvate ii. Acetyl CoA iii. Acetoacetyl CoA iv. -Ketoglutarate v. Succinyl CoA vi. Fumarate vii. Oxaloacetate Pyruvate, -ketoglutarate, succinyl CoA, fumarate and oxaloacetate can serve as precursors for glucose synthesis through gluconeogenesis.Amino acids giving rise to these intermediates are termed as glucogenic. Those amino acids degraded to yield acetyl CoA or acetoacetate are termed ketogenic since these compounds are used to synthesize ketone bodies. Some amino acids are both glucogenic and ketogenic (For example, phenylalanine, tyrosine, tryptophan and threonine. Catabolism of amino acids The important reaction commonly employed in the breakdown of an amino acid is always the removal of its -amino group.
    [Show full text]
  • L-Proline and Glutamatergic Neurotransmission: Clarifying The
    L-Proline and Glutamatergic Neurotransmission: Clarifying the Modulatory Role of Neuronal L-Proline Transporter Dissertation zur Erlangung des Doktorgrades (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn vorgelegt von Daniel Schulz aus Troisdorf Bonn 06.12.2011 Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn 1. Gutachter: Prof. Dr. Eva Kostenis 2. Gutachter: Prof. Dr. Klaus Mohr Tag der Promotion: 26.03.12 Erscheinungsjahr: 2012 Die vorliegende Arbeit wurde in der Zeit von April 2007 bis November 2011 am Institut für Pharmazeutische Biologie der Rheinischen Friedrich-Wilhelms Universität Bonn unter der Leitung von Frau Prof. Dr. rer. nat. Evi Kostenis durchgeführt. Abstract I Abstract The neuronal high affinity L-proline transporter (PROT) is a putative neurotransmitter transporter whose contribution to neurotransmission is still unknown. PROT is expressed exclusively in brain by subpopulations of glutamatergic neurons and is assumed to conduct the reuptake of L-proline, which is released upon depolarization. Since to date no specific high-affinity receptor for L-proline has been discovered, the amino acid has been suggested to play a role regulating glutamatergic neurotransmission. To uncover the in vivo modulatory function of PROT, a mouse strain lacking functional PROT was generated and confirmed. The analysis of these PROT-knockout mice provided new insights into the modulatory functional roles of this transporter. Biochemical alterations within the central nervous system of PROT lacking mice were identified. Thus, PROT-deficient mice exhibit increased expression levels of N-methyl-D-aspartic acid (NMDA), α-amino-3-hydroxy-5 methylisoxazolepropionic acid (AMPA) and kainate (KA) receptor subunits.
    [Show full text]